Product Details
Product Name:
LY3200882 |
CAS No.:
1898283-02-7 |
Purity:
98.37% |
Supply Ability:
10g |
Release date:
2025/07/16 |
Product Introduction
Bioactivity
Name | LY3200882 |
Description | LY3200882 is a highly selective inhibitor of TGF-β receptor type 1 (TGFβRI). |
In vitro | LY3200882 effectively inhibits TGFβ-mediated SMAD phosphorylation in tumor and immune cells in vitro, demonstrates anti-metastatic activity in migration assays, and rescues TGFβ1 or T regulatory cell-suppressed naive T cell activity, restoring proliferation in immune suppression assays [1]. |
In vivo | LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vivo in subcutaneous tumors in a dose-dependent fashion. LY3200882 has shown anti-metastatic activity in vivo in an experimental metastasis tumor model (intravenous EMT6-LM2 model of triple negative breast cancer) [1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Solubility Information | DMSO : 4.36 mg/mL (10 mM), Sonication is recommended.
|
Keywords | Transforming growth factor beta receptors | TGF-βRI (ALK5) | TGFβRI | TGF-β/Smad | TGF-β Receptor | TGFβ | TGFbeta/Smad | TGF-beta | TGFbeta | TGF-b/Smad | TGFb | SMAD | Smad | serine-threonine | phosphorylation | LY-3200882 | LY3200882 | LY 3200882 | Inhibitor | inhibit | immune | ATP-competitive | anti-metastatic | Anti-cancer | ALK5 |
Inhibitors Related | Monocrotaline | DMH-1 | Hydrochlorothiazide | Chebulinic acid | Chromenone 1 | LY-364947 | BMP signaling agonist sb4 | Pirfenidone | A 83-01 | Galunisertib | Alantolactone | Pentabromophenol |
Related Compound Libraries | Highly Selective Inhibitor Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | TGF-beta/Smad Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:839699-72-8
$160.00 / 1mg
-
CAS:128988-55-6
$83.00 / 1mg
-
CAS:13997-19-8
$59.00 / 10mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$1.00/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2019-12-31 |